Business
Helix BioPharma announces Q3 2007 financial results
Helix BioPharma announces Q3 2007 financial results.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, June 13 /CNW/ - Helix BioPharma Corp. (TSX: HBP/Frankfurt:\nWKN 918864) today announced financial results for the third quarter of fiscal\n2007, ended April 30, 2007.\n\n\nHIGHLIGHTS\n----------\n- Awarded first U.S. patent for DOS47, a broad anti-cancer therapeutic\n candidate\n\n- Announced positive Phase II clinical results with Topical Interferon\n Alpha-2b in patients with human papilloma virus ("HPV") induced\n low-grade squamous intraepithelial lesions ("LSIL")\n\n- Signed L-DOS47 manufacturing agreement with Biovectra DCL\n\n- Presented L-DOS47 findings at Keystone Symposia meeting, "Antibodies\n as Drugs: From Basic Biology to Clinic"\n\n- Presented L-DOS47 findings at the fourth international conference on\n "Tumour Microenvironment" in Florence, Italy\n\n\nRESULTS FROM OPERATIONS\n\n\nThree and nine month period ended April 30, 2007 and comparative periods\n\n\nfor the previous year\n\n\nThe Company recorded a loss of $1,523,000 and $4,765,000 respectively for\nthe three and nine month periods ended April 30, 2007 for a loss per common\nshare of $0.04 and $0.13, respectively. In the comparative three and nine\nmonth periods ended April 30, 2006, the Company recorded a loss $1,360,000 and\n$4,122,000 respectively for a loss per common share of $0.04 and $0.13,\nrespectively.\n\n\nTotal revenues for the three month period ended April 30, 2007 were\n$864,000 (2006 - $1,099,000), resulting in a decrease of $235,000 or 21.4%.\nTotal revenues, on a year-to-date basis were $2,582,000 (2006 - $3,110,000),\nresulting in a decrease of $528,000 or 17.0%. Lower product revenues from the\nsale of Orthovisc(R) and no license fee revenue from the Company's biochip\ntechnology resulted in lower overall revenues for both the three and nine\nmonth periods ended April 30, 2007.\n\n\nCost of sales totalled $249,000 and $849,000 respectively for the three\nand nine month periods ended April 30, 2007 (three and nine month periods\nended April 30, 2006: $284,000 and $1,039,000 respectively). Though overall\nmargins were maintained, lower margins from sales of Orthovisc(R) product were\noffset by favourable Canadian dollar exchange rates versus the US dollar on\npurchases of Orthovisc(R).\n\n\nResearch & development costs totalled $1,113,000 and $3,086,000\nrespectively for the ...